3.97
price up icon26.84%   0.84
after-market Handel nachbörslich: 4.15 0.18 +4.53%
loading

Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten

pulisher
01:02 AM

Iovance Biotherapeutics Stock (IOVA) Opinions on FDA Competitor Rejection - Quiver Quantitative

01:02 AM
pulisher
10:08 AM

Iova Stock Surges 23.5% Amid FDA Approval and New CEO Appointment - AInvest

10:08 AM
pulisher
10:03 AM

Iovance Biotherapeutics’ Remarkable Surge: Time to Dive In? - StocksToTrade

10:03 AM
pulisher
09:18 AM

Iovance Biotherapeutics’ Unexpected Surge: Is It Time to Buy? - timothysykes.com

09:18 AM
pulisher
03:52 AM

Where are the Opportunities in (IOVA) - news.stocktradersdaily.com

03:52 AM
pulisher
Jul 22, 2025

Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralyt - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance stock gains as Replimune drug rejected (IOVA:NASDAQ) - Seeking Alpha

Jul 22, 2025
pulisher
Jul 22, 2025

Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis Evaxion Biotech, Inxmed, Aivita Biomedical, Iovance Biotherapeutics, Viralyt - MenaFN

Jul 22, 2025
pulisher
Jul 22, 2025

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth - simplywall.st

Jul 22, 2025
pulisher
Jul 21, 2025

Iovance Biotherapeutics Inc Inc. (IOVA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com

Jul 21, 2025
pulisher
Jul 21, 2025

Is Iovance Biotherapeutics Inc. a good long term investmentConsistently superior profits - jammulinksnews.com

Jul 21, 2025
pulisher
Jul 21, 2025

This Healthcare Stock Just Hit a 52-Week Low -- but Wall Street Sees 380% Upside - Yahoo Finance

Jul 21, 2025
pulisher
Jul 20, 2025

Iovance Biotherapeutics Inc. Stock Analysis and ForecastExplosive returns - printweek.in

Jul 20, 2025
pulisher
Jul 20, 2025

Zacks Research Issues Pessimistic Estimate for IOVA Earnings - Defense World

Jul 20, 2025
pulisher
Jul 19, 2025

What drives Iovance Biotherapeutics Inc. stock priceFree Risk Assessment Services - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

What analysts say about Iovance Biotherapeutics Inc. stockFree Stock Selection - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Jul 18, 2025
pulisher
Jul 18, 2025

Iovance: I'm Switching From Sell To Buy Despite Likely Approval For Rival Drug - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Iovance Biotherapeutics (NASDAQ:IOVA) Cut to Sell at The Goldman Sachs Group - Defense World

Jul 18, 2025
pulisher
Jul 17, 2025

Iovance Biotherapeutics’ SWOT analysis: TIL therapy stock faces challenges amid potential - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

Iovance BioTherapeutics Sees Positive Trends with New Appointments and Promising Cancer Study - StocksToTrade

Jul 17, 2025
pulisher
Jul 16, 2025

Iovance Biotherapeutics Appoints New Chief Financial Officer - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA) - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire

Jul 16, 2025
pulisher
Jul 15, 2025

IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics: Legal Woes Shake Investor Confidence - timothysykes.com

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Faces Legal Hurdles Amid Investor Concerns - StocksToTrade

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics, Inc. Appoints Corleen Roche as Chief Financial Officer, Effective August 6, 2025 - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionMulti Bagger Alerts - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Iovance Biotherapeutics Names Corleen Roche as Chief Financial Officer - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Citizens JMP reiterates Market Perform rating on Iovance stock By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Goldman Sachs downgrades Iovance Biotherapeutics stock to Sell on Amtagvi adoption challenges - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

Cambridge Investment Research Advisors Inc. Acquires 5,237 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World

Jul 15, 2025
pulisher
Jul 15, 2025

Amtagvi shows 61% response rate in less heavily treated melanoma patients - Investing.com Australia

Jul 15, 2025
pulisher
Jul 14, 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Levi & Korsinsky Reminds Iovance Investors of the Pending - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

IOVA FINAL DEADLINE ALERT: Hagens Berman Alerts Iovance - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire

Jul 14, 2025
pulisher
Jul 14, 2025

The Iovance Biotherapeutics Lawsuit: A Cautionary Tale of Investor Protection and Timely Legal Action - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Iovance Says Amtagvi Shows 49% Response Rate in Real-World Skin Cancer Study - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Iovance Biotherapeutics Reports 61% Response Rate for Amtagvi® in Third-Line Melanoma Patients - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Join Class Action Before July 14, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jul 14, 2025
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):